A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism
Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug for treatment of hypoglycemia in patients with Tumor-Associated Hyperinsulinism (tHI).